153 related articles for article (PubMed ID: 10080105)
1. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus.
Abe K; Takasaki Y; Ushiyama C; Asakawa J; Fukazawa T; Seki M; Hirashima M; Ogaki M; Hashimoto H
J Clin Immunol; 1999 Jan; 19(1):58-66. PubMed ID: 10080105
[TBL] [Abstract][Full Text] [Related]
2. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus.
Nagafuchi H; Shimoyama Y; Kashiwakura J; Takeno M; Sakane T; Suzuki N
Clin Exp Rheumatol; 2003; 21(1):71-7. PubMed ID: 12673892
[TBL] [Abstract][Full Text] [Related]
3. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus.
Bijl M; Horst G; Limburg PC; Kallenberg CG
Ann Rheum Dis; 2001 May; 60(5):523-6. PubMed ID: 11302879
[TBL] [Abstract][Full Text] [Related]
4. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
5. Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus.
Takasaki Y; Ogaki M; Abe K; Takeuchi K; Ando S; Tokano Y; Kobayashi S; Sekigawa I; Tsuda H; Hashimoto H
J Rheumatol; 1998 Jun; 25(6):1085-91. PubMed ID: 9632068
[TBL] [Abstract][Full Text] [Related]
6. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
[TBL] [Abstract][Full Text] [Related]
7. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
[TBL] [Abstract][Full Text] [Related]
8. Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients.
Martínez-Escribano JA; Hernández-Caselles T; Campillo JA; Campos M; Frías JF; García-Alonso A; Alvarez-López MR
Hum Immunol; 2003 Aug; 64(8):796-801. PubMed ID: 12878358
[TBL] [Abstract][Full Text] [Related]
9. Expression and activity analyses of CTLA4 in peripheral blood lymphocytes in systemic lupus erythematosus patients.
Hirashima M; Fukazawa T; Abe K; Morita Y; Kusaoi M; Hashimoto H
Lupus; 2004; 13(1):24-31. PubMed ID: 14870914
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD80/CD86 and CTLA-4 mRNA in peripheral blood mononuclear cells of the patients with systemic lupus erythematosus.
Liu W; Li J
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(3):247-9. PubMed ID: 15315339
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus.
Yang JH; Zhang J; Cai Q; Zhao DB; Wang J; Guo PE; Liu L; Han XH; Shen Q
Rheumatology (Oxford); 2005 Oct; 44(10):1245-54. PubMed ID: 15987711
[TBL] [Abstract][Full Text] [Related]
12. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus.
Liu MF; Li JS; Weng TH; Lei HY
Scand J Immunol; 1999 Jan; 49(1):82-7. PubMed ID: 10023862
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients.
Folzenlogen D; Hofer MF; Leung DY; Freed JH; Newell MK
Clin Immunol Immunopathol; 1997 Jun; 83(3):199-204. PubMed ID: 9175908
[TBL] [Abstract][Full Text] [Related]
14. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.
Lang TJ; Nguyen P; Peach R; Gause WC; Via CS
J Immunol; 2002 Apr; 168(8):3786-92. PubMed ID: 11937530
[TBL] [Abstract][Full Text] [Related]
15. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells.
Moosig F; Csernok E; Wang G; Gross WL
Clin Exp Immunol; 1998 Oct; 114(1):113-8. PubMed ID: 9764612
[TBL] [Abstract][Full Text] [Related]
16. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
17. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.
Wong CK; Lit LC; Tam LS; Li EK; Lam CW
Rheumatology (Oxford); 2005 Aug; 44(8):989-94. PubMed ID: 15870153
[TBL] [Abstract][Full Text] [Related]
18. The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy.
Takasaki Y; Abe K; Tokano Y; Hashimoto H
Intern Med; 1999 Feb; 38(2):175-7. PubMed ID: 10225679
[No Abstract] [Full Text] [Related]
19. Defective antigen-presenting cell function in patients with systemic lupus erythematosus.
Tsokos GC; Kovacs B; Sfikakis PP; Theocharis S; Vogelgesang S; Via CS
Arthritis Rheum; 1996 Apr; 39(4):600-9. PubMed ID: 8630108
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of CD30 on CD3 T lymphocytes in patients with systemic lupus erythematosus.
Cabrera CM; Urra JM; Carreño A; Zamorano J
Scand J Immunol; 2013 Sep; 78(3):306-12. PubMed ID: 23790231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
